Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future-Reference-Cited by-同舟云学术

Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

Published:2021-03-09 Issue:4 Volume:109 Page:867-891
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Rayner Craig R.¹²,Smith Patrick F.¹,Andes David³,Andrews Kayla⁴,Derendorf Hartmut⁵,Friberg Lena E.⁶,Hanna Debra⁷,Lepak Alex³,Mills Edward⁸,Polasek Thomas M.¹⁹¹⁰,Roberts Jason A.¹¹¹²¹³,Schuck Virna¹,Shelton Mark J.¹,Wesche David¹,Rowland‐Yeo Karen¹

Affiliation:

1. Certara Princeton New Jersey USA

2. Monash Institute of Pharmaceutical Sciences Monash University Melbourne Victoria Australia

3. University of Wisconsin‐Madison Madison Wisconsin USA

4. Bill & Melinda Gates Medical Research Institute Cambridge Massachusetts USA

5. University of Florida Gainesville Florida USA

6. Department of Pharmacy Uppsala University Uppsala Sweden

7. Bill & Melinda Gates Foundation Seattle Washington USA

8. McMaster University Hamilton Ontario Canada

9. Centre for Medicines Use and Safety Monash University Melbourne Victoria Australia

10. Department of Clinical Pharmacology Royal Adelaide Hospital Adelaide South Australia Australia

11. Faculty of Medicine University of Queensland Centre for Clinical Research The University of Queensland Brisbane Queensland Australia

12. Departments of Pharmacy and Intensive Care Medicine Royal Brisbane and Women’s Hospital Brisbane Queensland Australia

13. Division of Anaesthesiology Critical Care Emergency and Pain Medicine Nîmes University Hospital University of Montpellier Montpellier France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2198

Reference208 articles.

1. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

2. History and development of antimicrobial susceptibility testing methodology

3. Methodological features of clinical pharmacokinetic–pharmacodynamic studies of antibacterials and antifungals: a systematic review

4. Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

5. Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Animal Models in Regulatory Breakpoint Determination: Review of New Drug Applications of Approved Antibiotics from 2014–2022;Journal of Personalized Medicine;2024-01-19

2. Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective;Antibiotics;2024-01-11

3. Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171;Antimicrobial Agents and Chemotherapy;2024-01-10

4. Model-Based Learn and Confirm: Designing Effective Treatment Regimens Against Multidrug Resistant Gram-negative Pathogens;International Journal of Antimicrobial Agents;2024-01

5. Optimizing Antimicrobial Treatment Schedules: Some Fundamental Analytical Results;Bulletin of Mathematical Biology;2023-11-23